---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-267465"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2026-06-11T20:01:15+00:00"
generated_at: "2026-06-11T20:02:11.556261+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa stockholders elect three Class II directors, ratify Deloitte as auditor

## Summary
- Andrew Schiff, M.D., Chandra P. Leo, M.D., and Anthony Manning, Ph.D. elected as Class II directors for three-year terms ending 2029.
- Schiff received 71.4M votes for, 741K withheld; Manning received 57.0M for, 15.2M withheld.
- Ratification of Deloitte & Touche LLP as independent auditor for FY2026 passed with 75.2M for, 58K against, 50K abstain.
- No other matters were submitted to or voted on at the June 11, 2026 Annual Meeting.

## SEC filing metadata
- accession: 0001193125-26-267465
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2026-06-11T20:01:15+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000119312526267465/0001193125-26-267465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000119312526267465/glue-20260611.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-267465
- JSON: https://secwatch.observer/filing/0001193125-26-267465.json
- Plain text: https://secwatch.observer/filing/0001193125-26-267465.txt

## Key facts
- Shareholder Votes
  Monte Rosa Therapeutics, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-11 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826457/000119312526267465/0001193125-26-267465-index.htm
- Shareholder Votes
  Monte Rosa Therapeutics, Inc. shareholders approved Election of three Class II directors: Andrew Schiff, M.D., Chandra P. Leo, M.D. and Anthony Manning, Ph.D. at the 2026-06-11 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: The stockholders of the Company elected Andrew Schiff, M.D., Chandra P. Leo, M.D. and Anthony Manning, Ph.D. as Class II directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2029 and until their successors have been duly elected and qualified or until their earlier resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826457/000119312526267465/0001193125-26-267465-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.